Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is collaborating with scientists from Lonza Biologics. According to the announcement, the two companies are working to present convincing evidence that PBIO’s patented BaroFold(TM) high-pressure protein disaggregation and refolding process provides significant advantages in cost, efficiency and environmental impact remediation compared to current methods widely employed in biomanufacturing protein drugs. Lonza AG is a world-renowned global biopharmaceutical contract development and manufacturing organization (“CDMO”). Data generated by Lonza and PBIO scientists was presented at last month’s annual Recent Advances in Fermentation Technology (“RAFT”) meeting.
The presentation showed that PBIO’s BaroFold platform has the potential to revolutionize the biomanufacturing of proteins in bacterial cultures by disaggregating, unfolding and facilitating the refolding of protein molecules back to their desired, “native,” biologically active configurations, which significantly improves the quality and lowers the production costs of protein therapeutics. “Demonstrations like this one on the effectiveness of high-pressure protein refolding should accelerate the adoption of the BaroFold platform by the biopharmaceutical industry,” said Pressure BioSciencesx president and CEO Richard T. Schumacher in the press release. “As BaroFold users become ready to scale up, we will support the establishment of BaroFold manufacturing sites under expanded licensing and contracting engagements. We estimate that BaroFold Manufacturing Systems would likely generate several million dollars in contract design, manufacture, installation and qualification contracts for PBIO. As previously stated, we believe the various BaroFold platform systems and the ongoing utilization and support fees associated with installations could eventually grow into annual revenue exceeding $100 million for PBIO.”
To view the full press release, visit https://ibn.fm/pgqfH
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. PBIO’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics and counterbioterrorism applications. The company has recently expanded market opportunities with the acquisition of the BaroFold patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM), which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
